Viemed Healthcare, Inc. announced its financial results for the first quarter ended March 31, 2025, reporting total revenue of $59.1 million. This represents a robust 16.9% increase compared to $50.6 million in Q1 2024. Net income attributable to Viemed Healthcare, Inc. significantly increased by 63.8% to $2.6 million, up from $1.6 million in the prior year's first quarter.
Adjusted EBITDA for Q1 2025 grew by 26% year-over-year to $12.8 million, with the Adjusted EBITDA margin improving to 21.6%. The company's selling, general, and administrative (SG&A) expenses as a percentage of revenue improved to 48.1% from 49.0% in Q1 2024, demonstrating operational leverage. Operating cash flow for the quarter was $2.9 million.
Following this strong performance, Viemed tightened its full-year 2025 net revenue outlook upward to a range of $254 million to $265 million. The Adjusted EBITDA guidance was also raised to a range of $55 million to $58 million. This updated guidance excludes the impact of the pending Lehan's acquisition, which was announced separately.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.